Infliximab Concentrations in Participants with Moderate to Severe COVID-19

J Clin Pharmacol. 2024 Apr;64(4):490-491. doi: 10.1002/jcph.2388. Epub 2023 Dec 14.
No abstract available

Keywords: COVID‐19; infliximab; pharmacokinetics.

Publication types

  • Letter
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibodies, Monoclonal
  • Antirheumatic Agents*
  • COVID-19*
  • Humans
  • Infliximab
  • Treatment Outcome

Substances

  • Infliximab
  • Antibodies, Monoclonal
  • Antirheumatic Agents